How to Legalize Medical Psychedelics in Your Country — Tania de Jong on Australia’s Breakthrough
Watch on YouTubeVideo summary
Tania de Jong and her husband established Mind Medicine Australia in 2019 with the goal of advancing psychedelic-assisted therapy, inspired by groundbreaking research from Johns Hopkins and Michael Pollan. After initially facing skepticism regarding mental health diagnoses, their perspective shifted following a transformative psilocybin experience in the Netherlands that highlighted the potential for healing intergenerational trauma. Recognizing the capacity of these treatments to address critical issues such as homelessness, domestic violence, and depression, they expanded their reach by establishing chapters across Australia and training over 750 clinicians since 2021. Their advocacy efforts culminated in a massive public campaign that gathered more than 13,000 supportive comments from Australians, leading to a pivotal moment in November 2022 when a Therapeutic Goods Administration meeting was unexpectedly crowded with personal stories of hope. This momentum resulted in the historic rescheduling of psilocybin and MDMA from prohibited substances to controlled medicines on February 3, 2023, making Australia the first country to achieve this regulatory milestone.
Following the regulatory changes, the landscape for psychedelic treatment has expanded rapidly, with authorized psychiatrists increasing from just one or two at the start of 2024 to 120 by mid-2026, and patient numbers rising from roughly 20 to nearly 400. Current data indicates that over 20 clinics operate across the nation, treating patients for conditions including PTSD, depression, addiction, OCD, and various physical ailments like fibromyalgia, with reported remission rates between 60% and 80%. While MDMA remains more prevalent in current usage, both substances are utilized under strict protocols that require ethics committee approvals. The Australian approach leverages real-world evidence collected through a registry at the Australian National University, demonstrating significantly higher efficacy compared to traditional treatments which often show only 10–15% remission rates. Although upfront costs for a full course can be substantial, ranging from $8,000 AUD for a single dose to up to $25,000 AUD including integration, the potential for lifetime cost savings and improved quality of life is considered a vital investment, supported by payers like the Department of Veterans Affairs and Medibank.
The success of this movement relies on building a comprehensive ecosystem that includes education, ongoing research, and engagement with healthcare providers, while acknowledging that psychedelics are not a magic bullet but rather a tool to open a window for neuroplasticity. Integration is crucial to sustaining remission, requiring lifestyle changes, social connection, and behavioral adjustments rather than a standardized approach, though group therapy models show promise in improving outcomes and reducing costs. Challenges remain, including bureaucratic hurdles regarding who can lead sessions, vested interests from researchers delaying access, and the emotional toll on staff facing personal attacks and high stress. Despite these obstacles, Tania de Jong emphasizes the importance of balancing persistence with acceptance, encouraging individuals to pursue their dreams despite fear or social friction, and fostering curiosity over reliance on artificial intelligence. The initiative concludes with a call to action for supporting patient funds, enrolling in educational programs, and joining advisory panels to continue walking each other home through shared humanity and inner exploration.
Read the full video transcript
We're standing in the kitchen and my
husband goes, "It's been rescheduled."
And I just said, "No, you can't be
serious."
And I said, "You've got to show me
this." And I read the document. I kept
thinking, "There must be an error in the
document. It can't have been
rescheduled." And no, it's been
rescheduled. So, we start dancing around
the kitchen. [laughter]
It's like, "This is unbelievable. This
is really amazing. We were so thrilled."
The headlines start coming out from
around the world. Australia has
rescheduled. Australia is the first
country to do this. Look at Australia
now. Australia's leading the world in
this field. And it's like, this is
surreal.
>> Where do you think it makes sense to
begin? I mean, we could just begin with
>> the trip treatment and how that domino
knocked over so many dominoes.
>> It did.
>> And then what you did?
>> Yes.
>> With all of the momentum of said
dominoes. Do you want to just begin
there and we'll just chat through it? In
2015,
I came across your blog. Well, I'd been
signing up to your blog for ages. I
mean, you know, I've been reading your
books and admiring your biohacking
courage to try all different things and
experiment for yourself cuz that's very
much how I also like to operate. I just
don't believe anything until I try it
myself.
>> Mhm. And so being that person that had
never had any alcohol really, don't
drink coffee,
never got high, never had any drugs in
my whole life until I read your Five
Bullet blog back in December, I think it
was 2015,
when you said that you had donated
$100,000
US to the Imperial college with
psilocybin for depression. I think it
was Tim.
>> Yeah. 2015 would have been John's
Hopkins with Roland Griffith. So there
was a depression study there.
>> That's right. So that was like a light
bulb went off for me and I clicked on
the link and I read the article and it
was a fascinating article in the New
Yorker magazine called The Trip
Treatment.
>> Michael Pollen.
>> That's right. By Michael Pollen,
>> the one and only. And I said to my
husband, "We have to do this." Like,
"Please read this article." And he just
I think he thought I'd lost it. And he
read the article and then he said, "Why
don't you see if we can get into a
trial?" And so we then approached Robin
Kart Harris, who has subsequently become
a great friend of ours. But at that time
it was like, "Well, can we get into one
of the trials in Europe?" And he said,
"Well, no, you don't qualify. you don't
have a mental illness diagnosis.
And then he proceeded to see if he could
introduce us to the psychedelic society.
And finally, we were introduced to a
guide in the Netherlands and we flew
over to Europe and we had this
extraordinary experience where we took a
large dose of psilocybin. But for me, I
had spent the previous 6 months, you
know, when we'd planned this, just
getting more and more nervous. I was
just like petrified.
>> Sounds normal. [laughter]
>> Yeah. And I was like, am I going to lose
my mind? What's going to happen?
Meanwhile, my husband's just not engaged
in it at all. And so, it got to the day
before where we're going to go and meet
this guide. And I wrote an email to my
accountant and [snorts] I said, "If
anything's to happen to me in the next
24 to 48 hours, these are my last
wishes." [laughter]
I was that scared. Scared of losing
control, scared of what this would all
mean. I'd never had any drugs in my
whole life before. And
was I going to go crazy? So anyway, we
went and my husband picked up the guy at
the airport. We were meeting him. He
surrounded him in his white robes, sort
of Rammes style, hippie Indian white
robes. Gave me a huge bear hug. Then my
husband asked him all the way back,
"Well, what is what's going to happen?
[snorts]
>> How does this work?" [laughter]
>> Yeah.
>> Play run a show for me. Yeah.
>> Right. And after 45 minutes, he was no
wiser. And then literally we the next
day took the medicines
with the guide and
yeah and we were blasted into multiple
realms of consciousness all different
dimensions of consciousness
and it was an extraordinary
experience as you well know it a sense
of being connected to self to others the
planet
Feeling like you're part of everything,
that everything's part of you. I think I
said to you last time we spoke that I
never saw a single piece of nature the
same since that day. So every seashell,
cloud, leaf, blade of grass,
just everything was transformed by that
experience and I could see the energy in
everything and my husband was also
completely blown away.
It brought us much closer together which
was also something we didn't well we
didn't plan for but it was a fantastic
bonus and we then just started going
what has just happened to us. So it was
such an extraordinary experience. It
took us about a year
to really integrate what had happened
and and we kept talking about it and you
know it was a true mystical experience
at the highest level. When you say it
took a year to integrate, was it really
just letting the snow globe settle and
seeing
what was discernible after things had
settled or were you
using therapy to talk through the
experience afterwards? What did
integration look like for you guys?
>> No, it was sort of the snow globe.
>> Mhm. Yeah.
>> Everything had sort of been [snorts]
blown, you know, like a huge fireworks
display. And actually, it was like a
fireworks display at times. And so for
us it was letting that settle and then
for me I'd thought, well there's no way
I'd ever do that again. Like it was it
was challenging. I mean it was beautiful
but it was also challenging because a
lot of material came up relating to my
ancestors probably relating to other
ancestral lineages that I'd had before.
And I thought there's no way I'm going
to do this again. But then as the year
went on and we were going to go back to
Europe again and stuff, I thought, okay,
well, maybe we'll we'll have another go
and see if it's the same or if that was
just a fluke or what happened. And so we
went back again and we work with the
same guide, Dutch guide.
And we had an even higher dose and it
was even more profound. And so by that
stage we said to one another, wow, well
if this is having this impact on us and
it was really healing us like personally
there was something going on. There was
some kind of magic. I mean, magic
mushrooms, but you know, it was like
there was some kind of
golden thread that was trying to
connect us back to ourselves, to
integrate us into ourselves and then
connect us to one another and to other
people. And we said to ourselves, we'd
already founded
five charities between us by that stage.
And we just thought, wow, well, if this
is happening to us, imagine if this
could be applied to all the people who
are suffering with like homelessness or
domestic violence or unemployment,
disabilities,
people suffering with depression that we
come across through all of our
charitable work. Because underpinning
all kinds of disadvantage
is usually some kind of mental illness,
some kind of trauma, depression,
something that has happened to that
person in their lives. And it's usually
that they've ended up being unemployed
or [snorts] committing domestic violence
or whatever it happens to be, but it's
through the intergenerational trauma
that they've experienced. And so Peter
and I just started looking and going,
well, let's meet all of the people
around the world. Let's go to all the
conferences.
Let's start meeting all the researchers.
And we did that. And we started meeting
researchers from all over the world,
which was absolutely extraordinary. And
we attended events and we learned
everything we could. We watched every
video. We listened to every recording
that we could. And then by that stage,
Peter and I were like, "This is
extraordinary." Like, and we spoke with
Rick Doblin at about that stage, which
was in 2018.
And in 2018, he said to me, Tanya, I
think you should set up a charity in
Australia to do this. And we were mad
enough to do that. And for people who
don't have the context just to just to
describe Rick briefly Rick is really one
of the primary drivers probably the
primary driver I would say and there are
a lot of people of course who have
played large roles behind
the psychedelic movement through this
organization called MAPS and they have
been predominantly focused on MDMA
assisted psychotherapy for PTSD and
that's been the main indication. So he
has been a fixture. He's very
unorthodox.
He is very well educated in policy,
incredibly colorful. He's just one hell
of a character. [laughter]
And uh I wanted people to have just a
little bit of um but he's been he's been
forging ahead since the 70s or 80s, well
before there was any kind of tip of the
hat from anywhere in the mainstream. So
that's Rick Dublin and he's very good at
helping other people and encouraging
other people. Yeah.
>> Absolute inspiration. He's dedicated his
whole life to this work and it's just
extraordinary and he was a total
inspiration to us as was Roland Griffith
and Robin and David Nut at Professor
David Nut the head of
neurossychopharmarmacology at Imperial
College London. Just amazing people
these legends. And um the thing was in
Australia we really didn't have a lot
going on. There was one trial in the
making. It was a trial for end of life
stress and anxiety through terminal
diagnosis which had been replicated in
other parts of the world like at New
York University and Johns Hopkins
University.
And we just knew that if Australia could
start to position itself in this space
that there might be a chance to heal a
lot of people. So we did start a charity
mind medicine Australia. We launched it
in February 2019 and we started working
in this field starting to work out well
how could we get these medicines to
Australians
as quickly safely accessibly as possible
and and cost effectively as well. We
originally approached the Therapeutic
Goods Administration, I think it was in
in late 2020,
and we asked them if it would be
possible if the medicines could be
rescheduled.
>> So, let me pause you. I apologize,
Tanya, just for
>> No, no, go for it.
>> The uh Yankees listening [laughter] and
others maybe. The TGA is roughly
analogous to the FDA in the US. So if
you want a new drug approved, if you
have something that is in a highly
restricted drug class and you want to
make it more readily available through
prescription with fewer controls, etc.,
then you have to contend with in our
case the FDA, but in your case the TGA.
Is that a fair way to put it?
>> Yeah, that's exactly right. And they're
these bodies require a lot of data and
evidence and generally speaking
pharmaceutical companies make
applications to them for the
rescheduling of medicines. And in this
case, we wanted to make an application
to move these medicines from prohibited
substances, which in Australia was
called schedule 9, but in the US is
called schedule one, to a schedule 8
medicine, which is a controlled
medicine, so that it could be used in
clinical environments. And so we started
applying to the TGA and we put an
application in at their encouragement
and then at the interim stage it was
knocked back and then at the final stage
despite many public submissions it was
also knocked back and so we thought
let's put it in again and one of the
things that the TGA has to do is it has
to provide its reasons for knocking it
back. So my husband who's an
extraordinary
intellect and
strategic I guess mind started really
working on these applications and really
addressing their concerns. And so then
we put in another application to
reschedule psilocybin MDMA for the
treatment of depression and trauma in
Australia. And again at the interim
stage the application was knocked back
and they had to provide their reasons
and then we put in a final submission.
And in that period there was another
public consultation period and over we
did this huge campaign and we were
educating people all the time through
this period. We were presenting webinars
and we were presenting talks to
politicians and health professionals and
anyone we could business leaders. We
were talking like we probably gave
thousands of presentations about these
medicines over that period. And then
finally we put in a submission and over
13,000 Australians supported this
submission through public submissions to
our therapeutic goods administration
supporting the medicine and over 98% of
people supported the rescheduling of
these medicines. And this was the
largest amount of public submissions
ever received by our regulators for
rescheduling any medicines. So there was
this huge pressure.
>> Yeah. I imagine not every one of those
recipients was super happy about the
volume. I [laughter] have to imagine.
>> Right. Probably cuz they had to publish
them all as well, you know. Oh wow. Like
on their platform. Yeah.
>> So a couple of questions. At that point,
was it still just you and your husband
who were working on this or had you
assembled the volunteers to assist you
guys in various ways? What did it look
like at that point?
>> No, it was like this massive movement by
then. I mean like we had started
chapters in communities all around
Australia. So we had over 30 chapters in
place like Byron Bay or Brisbane,
Darwin, Perth,
>> even chapters in New Zealand.
>> And that would be chapters of mind
medicine Australia. So it'd be like MMA
put in place name.
>> Yeah. People who were just like behind
this mission.
>> Mhm.
>> Yeah. Just chapters and chapters of
people.
>> When you have chapters, how did you I'm
just thinking of the challenges involved
with like retail and franchising or
whatever. Like quality control and
giving people
>> marching directions of some type.
>> When people would reach out, how would
you enable them or what materials would
you send them? What would you encourage
them to do? If you've got people in
Byron Bay and 29 other locations,
[laughter]
>> yeah,
>> across Australia, what would you guys
send to them?
>> We had templates for everything. So, we
had precedents and templates and we had
how to actually do this. So, we made it
as easy as we could for the public to
put submissions in.
>> Mhm.
>> And we had volunteers in all those
places who were leading these campaigns
and getting a whole lot of people
together in those places. But in
addition to that, we also had
clinicians. So we had already started
training clinicians through our
worldleading certificate in psychedelic
assisted therapy. So we started that
training in 2021 and we've already
trained now over 750 clinicians. So
psychiatrists, psychologists, doctors,
nurses, o therapists, social workers,
counselors, you name it. We've trained a
lot of clinicians in Australia. So we
already had an enormous amount of
clinicians who were starting to put
pressure on their peak bodies and
professional bodies
>> as well as the general public. So there
was also an enormous amount of people
not necessarily in our chapters but just
people who just families you know had
people who were suffering with mental
illness in their families. There was
workplaces. So there was a lot of people
who had people in their workplaces
suffering with depression or trauma or
addictions. And people just started to
really jump on the bandwagon to start to
really learn about these medicines.
>> Mhm.
>> As sacred medicines.
>> And the medicines at that point, just to
define the molecules we're talking
about, that was MDMA and psilocybin.
>> Yes. Yes.
>> Let me bring us back for a moment to
David Nut. And the reason I'm going to
bring David Nut and UT back into the
picture is because in the process of
doing homework for this conversation
came across
a number of allies that you had
recruited over time, right? You really
had a multi-pronged approach and I want
to talk about some of those prongs.
>> Oh yeah, I forgot to mention that.
That's a big approach. [laughter] Yeah,
this is abc.net.au
and it mentions you engaging new
lobbyists. Hawker Britain known for
their cozy relationships with the labor
government who and it goes on da da da
understand the dynamics of CRA. The
organization then flew out Imperial
College of London
neuroscychopharmarmacologist David Nut
for a road show up and down the east
coast. Mhm.
>> And it goes on to mention him as one of
the celebrities of sorts in psychedelic
circles, certainly within scientific
circles. And I'm going back to the PC
here. During a whirlwind tour sponsored
by Herbal Tincture and Organic Chocolate
Brands, perfect. He addressed pack town
halls in Byron Bay, Sydney, and CRA, if
I'm pronouncing that correctly, and
Melbourne.
>> Then there were black tie events with
philanthropists and stakeholders at the
Australian clubs in Sydney and
Melbourne. It goes on and on.
>> Mhm. So, if there's any more color to
that, I'd love to hear it. Like, the
purpose of doing that.
>> Absolutely. I mean, that was a huge part
of it.
>> And the reason I'm bringing this up and
the part of the reason I wanted to have
this conversation is because you did
something very remarkable and you know,
there were other parties involved in a
lot going on. But I mean, MMA was a real
driving force behind some incredible
world first, like on the playing field
of [laughter]
sort of global
pharmarmacology and
mental health treatments. You've
accomplished something really
impressive. And there are pieces of the
playbook that I think people could apply
in other locations.
>> And this would be, I think, potentially
one example of that. So could you speak
to what you did with the road show with
David and maybe how you used lobbyists
and also like how did you pay for all
that? [laughter]
>> Well, I mean these are really important
questions and we are being asked by a
lot of other countries and organizations
how how we did it and it was very tough
but we we tried everything. So we never
gave up. That was one aspect and my
husband and I are very persistent
people. So every roadblock that we'd
get, we'd think, okay, what are we going
to do now? And we would climb around or
over or through that wall, whatever we
could do to keep going. So what happened
was in 2022,
David, who'd become an incredibly good
friend of ours and someone we deeply
respected and we just adore his humor
and and his intellect.
>> How did you first connect with David?
Cold email or how did that happen? Yeah.
I mean, so as you would see, we've one
of the other really strong prongs of our
strategy was to put together this
worldleading advisory panel.
>> And so we've got about 75 or so leaders
in this field or people who are really
great advocates for these medicines,
scientists, doctors, researchers, and
others. And I just started reaching out
to to people. But also in 2018,
I went to a conference run by Eona in
Madison in Wisconsin and I spoke at that
conference.
>> Yeah, that's that's a trip. It's a bit
of a trip for you.
>> Yeah, it was really
>> Eona for people who don't know is an
organization at least last I checked
predominantly focused on psilocybin.
>> Mhm. Correct. and their medicine's
likely to be registered as just about as
soon as Compass Pathways, another huge
pharma company who's an applicant for
psilocybin. Over the next 6 months or
so, we anticipate a number of these
medicines becoming registered medicines.
We can talk about that shortly, but back
to the time that we brought David Nut
out. So, basically, I had approached a
lot of people. I'd also met a lot of
people at Eona. And so
>> I then started inviting them to join our
advisory panel. And so that was how I
met Robin Roland, David Nut, all of
these people. And as we'd meet one
person, then they'd say, "Well, have you
met this person and have you met that
person?" And
>> let me pause you, Tanya, for a second
cuz I know you're persistent, but these
people get asked to do all sorts of
stuff all the time.
>> Yeah.
>> How did you make it easy or compelling
for them to say yes? Like what's the
pitch? What was the pitch to someone
like Robin? Right? Because at that
point, I'm trying to put a date to it,
but Robin at that point had probably
appeared, I'm just guessing on the
timeline here in How to Change Your
Mind. He's somewhat of a
>> main scientific protagonist or certainly
>> figure within How to Change Your Mind, a
book by Michael Pollen that really
>> shifted the tectonic plates of what was
possible for psychedelics
>> in the US and elsewhere. In some ways,
in a lot of ways, in many, if not most
of the best known philanthropists and
supporters of psychedelics, not all of
them, but a very high percentage,
>> would kind of reach back to that as the
tipping point for their interest. So,
how do you get then Robin's like the
hottest girl at the dance, right? And
he's very charismatic. He's good on
camera. He's good in audio.
>> I met them. I met them, Tim. you know
like I met most of them actually at the
Eona conference and also I happened to
sing at the Eona conference and speak.
So I gave a speech.
>> I spoke about what we were hoping to
achieve in Australia. Also sang.
>> Mhm.
>> I serenated Roland Griffith. It was
beautiful. I mean I miss that guy so
much. And so I met these people and we
just connected and they were inspired by
the fact that we were trying to move the
needle in Australia. I don't think that
they thought that we could do it.
>> And to be honest, I didn't know that we
could do it either. Like
>> it was just persisting and persisting
and so I think people just started
joining us because maybe they believe
that we could do it. I mean we had set
up five charities before that had
already done some significant things.
>> How did you end up speaking at the
conference? Right. Because that seems to
me
>> an important piece of the recipe for why
suddenly you could talk to them
afterwards. Right. and they were already
a warm audience at that point.
>> So, how did you end up speaking at that
conference?
>> Well, that was through Bill Linton. And
so, Bill Linton is the founder of Eona
and I'm sure you know and you know him
and he's just a lovely guy and again we
connected. I wrote to him.
>> What did you say to Bill in the email?
you know, I'd really like to speak at
your conference. And in fact, I think
they even had heard what we were doing
and that we were trying to do this in
Australia. And then they actually I
said, "Look, I can also sing."
>> Yeah.
>> And maybe that was part of it. And then
he just said, "Well, look, I'd like you
to come over. I'd like you to sing." We
I think we probably had a Zoom call or
something like that. And they then
invited me to speak and to sing. And it
was a long trip. It was a very long
trip. And literally, I had to get off
the plane. And It is a very long trim.
>> I was in an altered state. I was in some
time warp then the jet lag and
everything.
>> I wanted to sidebar quickly that
sometimes it is the weirdest, not that
singing is weird there. I have
[laughter] much stranger obsessions and
interests, but it's the most unexpected
maybe talents or side interests or fill
in the blank that you do on the weekends
and evenings. That sometimes is the
thing that opens the door.
>> Yeah.
>> Because it is the thing that other
people aren't leading with. Right. So
when you're like, "Oh, and I also sing."
And they're like, "You know what?
You know, she's scrappy. She's willing
to fly all the way from Australia. Oh my
god." Like to Wisconsin. Okay, sure.
Yeah, why not? Let's give it a shot.
>> Well, also I think by then I'd also had
that connection with Ramdas. Yes.
>> So that was also a help. I haven't
mentioned that and that was very
significant. So actually and I want to
come back to David not with you which I
really because that's really important
but back in 2016 after you'd
woken me up into this whole space and
then we did the medicine with this Dutch
guide. He played us some Ramdas at the
end of the medicine session and I went,
"Who's this guy? This is amazing." And
my husband's one of these guys who when
he hears someone really inspiring, he
goes, "Well, is there a way we could
meet them?" And so, okay, well, why not
try and meet Ramdas? So what we did was
we wrote to him via again his people and
we found out that you could indeed spend
a week living at Ramdas's house in
Hawaii and get to spend time with him,
you know, living there. So we were lucky
enough that we got to fly to Maui.
>> Well, hold on. How does that how does
that work? Cuz I'm sure a lot of people
would love to hang out with Ramdas.
>> Yeah. No, really.
>> What are the hurdles you have to clear
to live at his house for a week? Or how
does it work? or is it just pay for play
or how is it?
>> We made a donation and we got to live in
the in the house that was on his land
there and live right next to him and
then every day or two we'd get to hang
out a little bit with Ramdas.
>> Yeah, that's cool.
>> And so we'd come into the main house.
We'd spend some time meditating with
him. He'd invite us to some of the
ceremonies that he'd be having at the
house. We even went to the beach with
him because he had this incredible
wheelchair that had these amazing
inflatable tires and he'd be wheeled out
in his wheelchair out into the ocean and
one particular day there'd be two
rainbows that appear when Rames gets out
into the ocean. It was like pinching
yourself like is this really happening?
And a lot of it was sitting in silence
with him because he had had that stroke.
And by this stage it was it was about a
year or so before he actually would
pass.
>> And so
he was still vibrant though. And when
you looked in Ramas's eyes, you could
just see yourself reflected back in him.
And I remember singing to him as well.
And there were tears rolling down his
face when I sang to him. And it was a
song called Coming Home. It was all
about coming home to yourself. And but
the minute that we would mention
psychedelics to Ramdas, his eyes would
light up and he'd start talking about
you [snorts] know his time that he gave
his guru in India this huge dose of
>> craziest story
>> have you heard this story right and
nothing happened
>> it's in be here now and his guru in
India so Ramdas again just to provide a
little context for people who are like
what are they talking about Ramdas us
which is I believe servant of
>> God
>> of Rahm. Yeah. Servant of God is the
non-birthname of the man formerly known
as Richard Albert who was at Harvard
with Timothy Liry who some people may
recognize and they were both kicked out
of Harvard. uh little known fact in part
due to Andrew While then an undergrad
writing I think it was in the Harvard
Crimson about their dosing of psilocybin
and there was some discussion I don't
know if it was verified of them giving
it to undergrads and it became this huge
scandal and they were booted out and at
one point Timothy Liry was designated by
Nixon President Nixon as the most
dangerous man in America which is like
ridiculous in retrospect but [laughter]
there you have it and there's a lot more
we could say about that but suffice to
Richard Halper decides to go to India
and at one point he somehow finds his
way right this pre- internet pre-
smartphone somehow finds his way to this
guru
>> again we just described him be here now
>> Maharaji
>> yeah Maharaji and he's I think trying to
explain to him something about
psychedelics and he's like well do you
have any and he's like yeah I do and he
had promised LSD and he gave him it was
either 400 or 600 micrograms. This guy
had never taken any psychedelics,
>> took that and just sat there and clearly
would have set in and like an hour later
as if nothing was happening just kind of
looked at him with a smile and was like,
"I interesting."
>> Yeah.
>> And I think he said something like,
"Sure, you can like peek in and say
hello to Christ consciousness or
whatever you want to call it, but you're
not actually going to get to know
>> that's right
>> the depth." But the fact that somebody
could take 400 or 600 micrograms, to put
that in perspective, 100 micrograms is
considered a let's just call it standard
hit.
>> If I were to take 200 micrograms, I
would be completely incapacitated for 8
to 12 hours. So the fact that somebody
could take 4 to 600,
>> I think that would even happen to me on
50 to be honest, Tim.
>> Yeah. And could just carry on having a
conversation as if they only had a glass
of water is is somewhat mindboggling.
It's bizarre.
>> Ramdas went on to do a lot of writing
and a lot of recording and it's just
incredibly compelling,
>> prolific
>> to listen to.
>> So, you spent time with Ramdas.
>> We spent time with Ramdas.
>> So, the Ramdas card ends up being
helpful to get to
Madison.
>> Yeah, it definitely did.
>> And then Bill Linton and Co invite you
with open arms. You sing, you talk, you
meet this whole cast of characters,
including I'm guessing D. Was David not
there in Madison?
>> I'm not sure that David was there, but
Robin and Roland and and everyone else
was there.
>> Yeah, they're all stones throw from
David.
>> So then, this was like the year before
we started Mind Medicine Australia. So
then I wrote to David and I said, "We're
launching a charity. It's on February
the 13th." That was the date of our
launch. would you come to Australia and
speak at the launch? And so we flew
David to Australia. He spoke at our
launch which was at the University of
Melbourne and we then became very
friendly with David and his wife who's
delightful. And we've brought him over a
few times since then. And that launch
was packed out. And then what happened
was in I mean cut a long story short I'm
cutting through a whole lot of things
here but in 2022
>> we invited him to Australia to present
at some town hall events in public but
then we also brought him to the
therapeutic goods administration and we
asked the therapeutic goods
administration if you know we could
present to them and we asked the head of
the therapeutic goods administration how
many people approximately would come to
the ing that we would have David KN
there. We would also have a woman there
whose husband had tragically lost his
life because he'd got depression and had
not been able to cope. I'll talk about
that very briefly in a second. So what
happened was the the head of the TGA
said, "Oh, there'll be probably 10 or 15
people that turn up to the meeting."
140 people turned up to the meeting.
Some of them were in the room, some of
them were on Zoom.
>> And these are all people internal to the
TGA. These are all employees or employed
by the TGA.
>> Yeah. They were like Department of
Health people, executives, you know, all
from all different parts of the
Department of Health and and the TGA.
And so what happened was we we had
invited this woman called Vanessa to
speakers just before David Nut. And
Vanessa's husband had got depression a
few years prior. just out of the blue
all of a sudden got depression really
badly and he woke up one day and he said
to her I need to go to a hospital and so
she took him to a doctor and they
started him on some SSRIs
anti-depressants
and then they didn't work and then he
got taken to an institution cuz he was
really unwell he was put in that
institution and they've got a young
daughter very successful man by the way
no previous history of depression just
came on.
And so he was put in this institution
that didn't help. They saw every
professor and expert that they could.
She's kept a 20page dossier of every
treatment she tried. During the middle
of him trying many, many treatments, she
rang me up and she said, "Tanya, you
know, I've heard about psychedelic
assisted therapies. Could Franco, his
name was Franco, could he get
psychedelic assisted therapies?" And I
said, "Look, no, not in Australia at the
moment. We're trying really hard to get
these medicines rescheduled, but he
would have to go overseas to do this
legally, like in the Netherlands where
psilocybin truffles are legal for
example or somewhere else. He was not
well enough to be taken overseas and
they didn't want to break the law by
going underground in Australia and this
applies to a lot of people. And so what
happened was they kept trying all the
different other treatments, the
professors, he was in the institutions.
She said to me, she rang me about
another year later, said, "He's begging
me to go every day. He wants to go. He
wants to leave.
Hang in there. We We're really working
hard on this." Anyway, he couldn't wait.
She had kept this 20page dossier. And
she got up in front of the TGA and she
said, "I believe that if my husband had
have had access to these treatments that
he might still be alive today and you
know that our young daughter would still
have a father." And you know this is all
the treatments we tried. It's not like
we didn't try to get Franco well. We
did. And there wasn't a dryer in the
room at this stage. And then Professor
Nut comes on and starts presenting about
the science and all the research, the
data, the evidence that by that stage
there'd been a lot of trials as you know
that had taken place. So he presented
and then we presented and
still everyone was going there's no way
this is going to happen. and there's no
way the rescheduling is going to happen.
There was scientists and and clinicians
and others that just said it's not going
to happen. But this was in about
November of 2022. And
we just kept,
you know, pushing. And then in February,
February the 3rd, it was 2023,
we're standing in the kitchen and my
husband goes,
"It's been rescheduled." And I just
said, "No, can't be serious." And I
said, "You've got to show me this." And
I read the document. I kept thinking,
"There must be an error in the document.
It can't have been rescheduled." And no,
it's been rescheduled. So we start
dancing around the kitchen. [laughter]
It's like, "This is unbelievable." We
were so like this is really amazing. We
were so thrilled. Then like the
headlines start coming out from around
the world. Australia has rescheduled.
Australia is the first country to do
this. Look at Australia now. Australia's
leading the world in this field. And
it's like this is surreal. This is so
incredible that this actually happened
in Australia because you know Australia
tends to be more of a follower than a
leader often. But to do this was
incredible. So then a few months later
the rules changed so that the
psychiatrist could actually start to
treat patients in clinics. And that was
the whole purpose of this was that there
should be clinics around Australia
with clinicians that we'd been training
since 2021 and that patients should
start to be treated with these
incredible sacred medicines with therapy
obviously. And so there was these
multidisciplinary teams and
psychiatrists could start applying to
the therapeutic goods administration for
what's called an authorized prescriber
status. So you psychiatrist put an
application into the TGA and we help a
lot of psychiatrists do these
applications because they're quite
ownorous and they have to put in their
protocols, how much medicine they're
going to use, where they're going to
practice from, all these different
protocols. And then those are reviewed
by the TGA and an independent ethics
committee. And if they get the TGA stamp
and the ethics committee stamp, they can
start using psychedelic assisted
therapy, psilocybin assisted therapy,
and MDMA assisted therapy in their
clinics. And so there's now over 20
clinics around Australia,
mostly led by clinicians that we have
trained through our certificate in
psychedelic assisted therapies and over
400 patients or so roughly have been
treated. Now, that doesn't sound like a
lot because there's millions of
Australians who are suffering with
post-traumatic stress disorder and
depression. And there's millions of
people globally suffering from these
conditions who are not getting well like
Franco.
And one of the arguments that was really
important for the Therapeutic Goods
Administration was there's a risk to not
doing anything. So if you don't do
anything, if you don't reschedule these
medicines, that's actually a risk
because patients who've tried everything
like Franco might end up taking their
own lives and that would be tragic. And
we through the period that we were
making these applications heard of other
stories than Franco. We had a lot of
people who write to us. They texted us,
they emailed us, and they begged us. We
even had politicians writing to us
saying they've got a son or a
constituent saying could we please
provide the medicines to them and we
said well no we can't until these
medicines are rescheduled. So we kept
having people begging us for the
medicines. We obviously couldn't provide
them. We're not a medicine provider. And
important to say to everyone that these
medicines you don't take them lightly.
You take them in a very controlled
setting. Personally, I love nature, but
we have to do it in clinics in Australia
under these circumstances
and it's really important for the
patient to have the right preparation
and mindset so that they can be open to
whatever is coming through the altered
state and then bring all of those
insights for their life, their work,
their health, whatever it happens to be
back into their life. And usually that's
done through therapy. So a patient goes
through a 3 or 4 month process protocol
and we are seeing 60 to 80% remission
rates in Australia which is replicating
what we've seen in trials around the
world. So of those 400 patients that
have been treated so far around
Australia
60 to 80% of those are going to
remissions and there's been no serious
adverse events. What does the pie chart
split look like for out of those 400?
How many are psilocybin for depression
versus MDMA, assisted psychotherapy for
PTSD?
>> So, more of them are MDMA. So, more
psychiatrists started out doing MDMA for
trauma.
>> It's probably a good idea. I think it's
good to get comfortable skiing the blue
squares before the black diamonds. Yeah,
>> right.
>> Tends to be more manageable. Many of the
psychiatrists felt more comfortable
administering MDMA first. There are some
patients in Australia, I think, who've
been administered both medicines, not at
the same time, but subsequently.
>> Mhm.
>> But it's probably about a 7030 split.
But psilocybin is starting to creep up.
And we're also seeing psilocybin now
being researched for a whole range of
other conditions as you know. So for
addictions and obsessivecompulsive
disorder, eating disorders,
>> cluster headaches, fibromyalgia, you
know,
>> I think MDMA is still very
underestimated as a tool. It's sort of
been in the zeicist long enough that a
lot of the writing or videos or podcasts
that get attention are focused on the
latest and greatest or what they might
consider the new kid on the block like a
5 MO DMT. Okay, everything's about five
Mayo DMT because it can be crammed into
15 minutes and it's the businessman's
path to God and all this stuff which
from a commercialization perspective I
understand but at the same time
[clears throat]
you have something that is already very
well researched and that has actually
been around a very very long time. I
want to say it's the 1920s when MDMMA
was first patented and then it was
shelved and then the patent expired and
then Sasha Schulen and his little lab
and his tasting parties conjured up
hundreds of psychedelics. If anyone's
ever heard of 2CB, 2CE, you can thank
Sasha Schulan.
>> But also resurrected MDMA, which
basically replaced MDA as a the
underground therapist's tool. And I
think MDMA is very underestimated.
>> Oh, so do I.
>> Given how broadly speaking, how
manageable it is relative to many of the
other psychedelics that we could
discuss.
>> Mhm. And I think partially because it
doesn't necessarily I would say pretty
typically does not provide the 17th
dimension shattered into stardust
technicolor grand finale fireworks show
which make for good stories, right? that
it gets under underestimated
as a tool
>> because it's maybe not making the rounds
at as many cocktail parties cuz you
can't it's unlikely you're going to be
like yeah and then this
>> these dancing crocodiles with sapphire
eyes came out and danced around me and
so and so which you know you'll
certainly get if you're hanging out with
your IASA friends. Mhm.
>> So MDMMA is really I think a tremendous
tremendous tool given the risk profile
given the the manageability of it
relative to other things. Question I
suppose related to the integration that
you already mentioned is the therapy
that acts as the kind of lattis work of
support for these experiences in
Australia. Is it standardized or is it
really up to the clinician and the
patients to select the therapeutic
modality? Is it standardized perhaps in
the way that that MAPS was trying to
standardize with like IFS informed
diads and things of this type?
>> So it's not standardized
and many of our clinicians, the ones
who've done our certificate in
psychedelic assisted therapies,
you know, use a whole lot of different
modalities. So yes, some of them may use
parts and IFS therapy, internal family
systems therapy, or they may use other
types of therapy. So there's all sorts
of different therapies that we encourage
our clinicians to look at. And that
might be and I feel like one of the
things that's becoming most important is
even just nutrition. So just coming out
of this experience and having the right
nutrition because if you go back into
your life and just start eating all say
if you were eating a lot of sugar before
or drinking a lot of alcohol and you go
back to that well then you're probably
going to relapse. So there's all sorts
of things around nutrition and exercise
that we're hoping will be more and more
included as integration therapy post
treatment for anyone doing psychedelic
assisted therapies. But we don't believe
that there should be a cookie cutter
approach. Every therapist has different
skills that they bring to the table. And
many of them, most of the therapists
that we're training are trauma informed,
but not all of them.
>> And they're just learning, you know, and
they're learning to bring their own
skills and work out what works for each
patient. And I think that matters a lot
because everyone that we're treating
through these clinics, they're all
individuals and not everything's going
to work identically for every patient.
just the same way that the dose of the
medicine is not going to be identical
for each patient.
>> How many patients would you hope? Not in
a pie in the sky, best case, green
lights all the way scenario, but in a
kind of base case, right? Not worst
case, not best case, kind of right down
the middle case. How many patients do
you think could be served with these
medicines over the next 3 years in
Australia? What do you think? Well, it's
an exponential thing. So, we're seeing a
huge exponential growth. So, just even
now as we speak, we just found out that
now there's 120 authorized prescribing
psychiatrists in Australia for either
MDMA or psilocybin or both medicines.
So, that is a huge jump. You know, we
started with one or two psychiatrists
back at the start of 2024. We're now at
the middle latter part of 2026.
And that is an exponential increase in
authorized prescribing psychiatrists.
[clears throat and snorts]
>> In the first year, we trained about 80
therapists. We've now trained 750.
In the first year, only a handful of
patients. Maybe I don't know 15 20
patients were treated. Now there's been
nearly 400. So maybe it will get to
5,000
by then. This is me being conservative.
>> [laughter]
>> Yeah. 5,000. Yeah.
>> Well, it could be a lot more,
>> but maybe 5,000 is a realistic number.
>> Mhm.
>> But that's a fraction of who needs it,
>> right? Which I understand,
>> but I don't want to
let the dream of boiling the ocean kind
of minimize the impact of even 400
people. Because what people listening
may not realize is that if you look back
at the early studies, if you look at a
lot of current studies, they are
expensive,
>> right?
>> At least in the United States. I'll
speak for the United Well, speak for the
United States. What a sentence. I will
speak to some of the clinical trials in
the US, many of which I've been involved
with. And because these compounds are
still schedule one, it is incredibly
difficult, timeconuming and expensive to
recruit subjects to get approvals
through ethics boards, IRBs, etc. And as
a result, what you could get on the
street very easily, mushroom chocolates
or otherwise for $50 for a patient in a
proper clinical trial run at a
university will cost could cost $15,000
per person, right? I mean, something
like that. It is incredibly expensive.
And what that means is you end up with
these studies that are welldesigned and
hopefully properly powered. And people
can dig into that if they want online.
and if they want to read up on what that
means from a statistical perspective,
but you end up with 10 people, you end
up with eight people. Maybe you end up
with 15 people. Certainly, if you're a
for-profit company, Compass and others
have been able to and have had to have
larger sample sizes and larger cohorts
and so on and so forth as you move
through the different phases.
400's a lot, but there's a big butt and
I'm hoping you can tell me the answer.
I'm sure you can. Is there some type of
requirement for data reporting from
people who are authorized because it's
most valuable as a way of building
momentum
>> and creating a virtuous cycle if there
is mandatory data reporting
>> that then provides a signal.
>> Yes.
>> Or many signals.
>> Well, no. And that's a really important
part of our strategy. So our strategy at
Mind Medicine Australia was to build the
ecosystem so that we could make sure
everyone was trained that the public and
clinicians were fully educated and we
keep doing that that there is ongoing
research for new conditions
that clinical rollouts and the medicine
supply can happen very smoothly and then
there's the whole pay part which I'll
come to you so there's the whole cost of
it all
>> but the data collection is really really
important and one of the things David
Nut did with us was he was really like
we have to make sure there's real world
evidence being collected. So he worked
with professor Paul Fitzgerald at
Australian National University and mind
medicine Australia has funded a registry
which we have no influence on. we simply
funded at the Australian National
University which collects real world
evidence the data from the baseline of a
patient when they go in for the
treatment then what they're like when
they come out of the treatment and
that's being collected all the time. It
hasn't published yet but we hope that it
will publish over the next few months
and then continue to publish
periodically as they collect more and
more data. And this data is critical
because this is what can show the
government well firstly they know
there's been no adverse events serious
ones because there's been nothing
reported to the TGA but it's also really
important to show the government wow
well these remission rates around 60 to
80% that's compared against 10 to 15%
for existing treatments for PTSD and
psilocybin with MDMA and psilocybin
treatment for depression and trauma in
Australia at the moment. So 10 to 15%
versus 60 to 80% remission rates. That
starts to become very important for a
government because they go well wow
there could be some serious cost savings
here.
>> Mhm.
>> We could save millions, tens of
millions, hundreds of millions of dollar
over the course of a patient's lifetime.
And one of the other things we've done
at MMA is we've helped to really bring
on the payors for these treatments. So
we now have the department of veterans
affairs who are supporting treatments
for veterans. We have the national
disability insurance scheme also funding
treatments and we have Medi Bank which
is our largest health insurer who have
basically said that any eligible gold
members of Medybank can get pretty much
the whole treatment cost paid apart from
a couple of thousand dollars. So
everyone's shifting to Medybank. What
does it look like to recruit any of
these payers? So, how do you even bring
the first of these payers online? What
does the outreach look like?
>> We went to them all from early on. So,
we were talking to the Department of
Veterans Affairs from early on. Yeah.
>> Because we had seen what had happened in
the US with veterans and we knew that
that was a core strategy that Rick Dolin
and MAPS had also used. And it's an
important strategy because veterans and
first responders have served their
nation and more veterans die through
their own hands through suicide than die
on the battlefield. And they experienced
so much trauma in the work that they've
done. And we knew that the Department of
Veterans Affairs was really struggling
with the amount of veteran suicides that
were occurring. So they were someone we
started talking to and presenting to
from very early on in our time as Mind
Medicine Australia. The National
Disability Insurance Scheme came on
board because they obviously want to try
and reduce the costs of treatments and
this is a really good way to reduce
costs over time. Though the cost of the
treatment is relatively expensive
upfront
over the course of a patient's lifetime
the potential cost savings are enormous.
Rick Dolblin and MAPS did some economic
modeling and showed that the cost per
patient this was a few years ago already
could be well over $100,000 US of cost
savings. So we knew that cost would be a
barrier. And so we also started a
patient support fund at Mind Medicine
Australia. And how we managed to do a
lot of this was through our own
philanthropy in the end. Yeah. We've
we've also donated a lot of money to
this. Peter and I have done this pro
bono for the last 8 years completely pro
bono because we just want to help
alleviate suffering and want to see
people get their lives back.
>> Couple of
questions all over the map. Is it true
that you with your facilitator from the
Netherlands were given psilocybin with
Syrian rue or was there no Syrian rue?
>> No, it was Syrian rue.
>> Why did he decide to include that? My
understanding and I haven't looked this
up in a very long time is that Syrian
rue contains could be multiple
betaarbines like harm, harm,
>> paganum hamala.
>> Right? So peanum carala is the Syrian
root
>> but it imparts when combined with
psilocybin a kind of a an iawaska twist
of lemon on top.
>> It does
>> because it's adding the monomine oxidase
inhibitors.
>> Why did he choose your facilitator to
approach it that way?
>> I think that was the protocol that he
used.
>> Mhm.
>> Anyway, it was his standard protocol.
Now I think it's a great protocol for
the right clients. I think for us it was
the right protocol.
Firstly it's an MAOI inhibitor as you've
just mentioned. So he has this protocol
which he calls psilowca. So it's a
combination of psilocybin and iawaska.
That's how he sort of
describes it. Now when I went in if I'd
known that it was Iawaska I probably
would have freaked out and gone oh
there's no way I'm doing Iaska. But it
was the way that it was done was
actually it was like that. And I think
that because Peter and I had never had
any drugs in our life at all. You know,
we were completely new to this. But we
were also type A people.
>> You don't say.
>> Right. And I was a bit of a control
freak then. I'm still one, but I'm not
as much one now as I was then. I will
say that. And that was one of the
reasons I wanted to do this was I wanted
to let go of some of the control, right?
So I really wanted to see what that
would be like. What would Tanya be like
without all of that holding on?
>> Good for you. A lot of type A people
will not, you know, choose to release
the white knuckling,
>> right? So, it was like this Syrian rue,
it relaxed us firstly, but then the
goal, which I found out later was that I
didn't know this at the time, but that
it was expanded the visuals and the
whole experience between two to 10
times.
So it amplified our experience and what
we would have seen, heard,
everything experienced by two to 10
times and subsequently I think that is
accurate. I think it extended the
experience. It created more visuals than
what I had seen say without using pegum
pala in subsequently. But the first two
experiences Peter and I had both were
with Siri and
>> Rue.
>> And I thought it was an extraordinary
way of relaxing us and then helping us
to just let go of of our bodies and just
to be able to travel. And at one stage
the guide said, "Oh, you guys are really
having a lot of trouble stepping out of
your bodies." [snorts] I could hear him
say that in the room. [laughter]
>> You're like, "Thanks, bud."
It was like your body's fighting you.
>> I'm curious what dose. Do you recall how
many grams of I'm assuming it was dried
salass mushroom of some type
>> with a kick of lemon juice? Yes.
>> The lemon. Did he let it marinate in the
lemon for a while? Like did he grind it
up and then marinate it?
>> Not so long.
>> Okay.
>> Well, I don't know how long he'd
marinate it for. I was too petrified to
really watch that part.
>> How quickly did you feel the onset?
That'll probably tell me how long it
marinated.
>> I started feeling tingling through some
of my, you know, feet and hands.
Probably within about 30 minutes.
>> My husband kept saying, "There's nothing
happening." And then all of a sudden it
was like, "Oh my god."
>> Famous last words.
>> Yeah. Like I mean, he was on the floor
on a mattress. I was on the bed. We were
not talking to one another. That was
part of the sort of protocol. [snorts]
>> And it probably took about half an hour.
And I could feel like there was so much
tingling. I called the guide over and I
said, "Hey, I'm really afraid. Can you
hold my hand?" Because I thought,
"What's happening?" I hadn't felt my
body do these sorts of strange things
before. And it was like I could feel
myself sort of it was like I was filling
up and I didn't quite know what that
meant. And then all of a sudden, I
started to see the colors and the shapes
and
>> Mhm. [clears throat]
It was like this kaleidoscope that I was
looking through and it was incredible.
>> I mean, I'll be curious if this matches
your experience because I I do have some
experience with psilocybin plus Syrian
R. Also, just a footnote for folks on
the lemon.
>> The lemon. Yeah. My understanding, I'm
not a biochemist, but if you marinate
the salby mushroom, especially if it's
ground up in say a coffee grinder in
lemon, that it basically pre-
metabolizes it, breaks it down or
converts it into psilocin. And your body
is converting psilocybin into psilicin
as the active metabolite to begin with.
>> And in doing so, like for me, it would
typically take in some cases, it really
depends on a lot of factors. when did I
last eat, etc., etc. But 45 minutes to
an hour maybe for effects to really set
in with eating mushrooms if they're
ground and put in
lemon
and it depends on the strain of
mushrooms. Some can be more obviously
potent than others, but [snorts] 10 to
15 minutes, I mean I am off to the
races. like what normally would have
taken like 60 to 90 minutes which is
actually quite nice because the the
waiting game can be the most torturous
part for a lot of people. Similarly with
the Syrian rue my experience is let's
just say if my workspace
functional dose is 4.5 g let's just say
keep or like 3.5 to four these days
let's just say although I've taken the
foot off the gas a lot with this stuff
but if Syrian r is involved then all of
a sudden like 1.5 is plenty and you can
use much less which I think an one
advantage of that is that you're less
likely to have a headache the next day.
Some people at higher dose psilocybin
can really get a a crusher of a headache
depending [laughter]
on their sort of individual
pharmacology. So have you continued to
work with the Syrian ru or have you
moved to sort of a different toolkit
>> sometimes? Yeah. Yeah. And I, you know,
I'm sort of curious again to actually I
I have this hankering at the moment to
to perhaps go and have a session with
Syrian row again. I think that it's more
powerful for me still.
But subsequent to the second dose, so
when we had the second dose with the
guide, yeah, it was probably about 2.53
g of dried mushroom that we were having
to your earlier question.
And I guess the next one we had after
that was probably with a guide somewhere
in the US who
didn't use the Syrian. And
for me that was not as powerful. Like it
was still good.
>> I was still traveling quite a lot. And I
think Eldest Huxley famously said you
know once the doors of perception open
you can never shut them again. And I I I
really have found that to be the case.
You know what I saw I can never unsee.
what I experienced I experienced and
it's always going to be there with me
and I consider that the greatest gift
that I had that and it enables me to get
into other transcendental states with
meditation and singing and other things
much more quickly and easily as well. I
can access those states more easily.
Would I prefer to do Syrian rue from
time to time? Yes, I think so. It is a
good thing. Some people find it a bit
nauseating. So there are some people who
might find that it can make them a bit
nauseating.
>> I don't get a headache from psilocybin
generally speaking. In fact, a lot of
people I know use psilocybin to micro
dose to remove their cluster headaches
and their migraines. So it's interesting
that you said about the headache. So
everyone's different of course. Yeah, I
think this is a paraselis the dose makes
the poison situation in the sense that
micro doing certainly there are there's
research being done with LSD or analoges
of LSD looking at cluster headaches very
specifically
>> and a lot of the data I think are
compelling when I'm talking about
headaches generally what I'm talking
about is someone who is relatively naive
to psilocybin and this is most people in
the beginning innings who are
subconsciously or consciously trying to
remain in control. And so they have
three grams. They also don't know what
to expect. So when the facilitator
shuffles over and puts a hand on the
shoulder and says, "DA,
how are you feeling? Are you feeling
anything?" You're like, "I have no
[ __ ] idea." That's what [laughter]
99% are going to be like. I don't know
if I'm feeling anything. I have no idea
if this is the right thing or if I'm
just making things up.
>> Yeah.
>> Okay. And then depending also on how
seasoned the facilitator is, but they'll
they'll say, "Well, if you're going to
boost, this is the time to boost."
>> Yes.
>> And again, 99% of newbies are going to
be like, "I have no idea if I should
boost." But if they're not clearly
feeling something and they imagine it's
supposed to be this explosive
17th dimension experience, they're like,
"Sure, I'll have more." So they have
three, then they have six, and then I've
seen people have nine, and then some
people go like 12. In in a case like
that, the likelihood of having headache
is non zero. [laughter]
>> No, no.
>> When you start getting up into like the
brood force.
>> Oh, no. Definitely
>> flood doses, which it it happens a lot.
I mean, moms also frequently need higher
doses than some folks because they're so
used to taking care of everybody else.
>> Yeah. And [clears throat]
also sometimes a good reason for people
to do sessions separately as opposed to
as a couple.
>> No, that's true.
>> Uh if someone is like a primary
caretaker, sometimes they can be so
preoccupied that they don't respond to
what is already a saturating dose.
>> That's true. But there is also something
very much to be said for doing this in
groups.
>> Yeah, I agree with that. We've seen that
especially with the just the experience
but also then the integration like just
sitting in circle together in sacred
circles and
sharing these experiences with others.
It's just you can't bottle it. I mean
everyone's experience is so different
and it really helps you to understand
just how different we really are. But
then we're getting the same sort of
messages coming back. So even though the
material is so different that we're
seeing and hearing and feeling, but then
our insights coming back can be very
similar. And it's amazing how many
people, for example, that I've met
who've literally stone cold stopped
alcohol after having psilocybin
experiences
>> and never had it again.
>> Yeah.
>> Remarkable.
>> The group experience, I mean, the group
dynamic, I think, is where a lot of gold
is. And I think it was either 2014
or 15 where I funded a study at UCSF in
Northern California looking at long-term
demoralization, effectively a variant of
depression in AIDS survivors. And the
reason that I funded that study, I mean,
there are a number of reasons that I
helped fund it. And I'm not sure if I
funded the entire thing or part of it.
That's beside the point. The point is
that the reason it most grabbed my
interest is it was the first time I had
seen group integration
>> in the study of design. And I could
foresee or I would bet at least at that
point and I still bet that not only will
it be much more cost effective
>> absolutely
>> to deliver some of these medications in
group environments because you're
splitting the cost of one or two
therapists/babsitters
slash nurses across multiple people,
right? four, six, whatever the number
might be. I actually think, and this is
certainly borne out in the data from a
number of the better Ibegan clinics, the
outcomes are better. It's not just that
the cost is lower, the outcomes are
better
>> and certainly I think the experience is
much more nuanced and deeper for the
participants. So, I do think there's a
lot there. Let me come back to MMA. And
every time I say it, I think of mixed
martial arts, but I know it's not mixed
martial arts
>> or magic mushrooms Australia, like that
was sort of the secret name behind the
real name. [laughter]
>> Got it. Okay. Right. So, Mind Medicine
Australia. What are some of the mistakes
that you made, right? Because if
someone's listening to this and they're
like, "We want to take a playbook. We
want to try this in Croatia, we want to
try this in Japan, we want to try this
in fill in the blank,"
>> right? What are some of the cautionary
notes or the things on the do not repeat
list where you're like, you know what,
if I were to do this all over again, I
would probably not do X or I would do Y
a little differently. What are things
that come to mind for you?
>> There's so many things really like it
was it was really challenging. I mean
though my husband have set up so many
charities and and very successfully,
this was very difficult because it's a
very nuanced area. the whole area of
mental health care. There's a lot of
people that have a lot of views and
there's a lot of vested interests in the
space that we hadn't fully appreciated.
So there was vested interests from
researchers that we were not aware of
where researchers were wanting to just
keep researching for many many more
years. We had people literally confront
us and we had a lot of conflict with
researchers saying, "Well, we need to
research for another five or 10 or more
years and we're arguing, but there's
patients out there who are going to take
their own lives if they don't get other
solutions for their mental health
conditions." So, there was that sort of
thing.
>> Can you say more about that? When you
say vested interest, did they feel
because they are researchers and in the
business of conducting science,
>> did they simply feel that the burden of
proof had not been addressed, therefore
we need more data or was it, hey, we are
receiving funding from I don't know what
the equivalent of the NIH is in
Australia, but like we have we want to
continue to receive funding to research
these things. Therefore, the longer the
runway we have, the more my job security
is assured and therefore dot dot dot. I
mean, when you say vested interest, what
do you mean?
>> That was the main reason. I mean, that
was and you know, look, we understand
we've actually invested ourselves as we
know you have in trials that are for
innovative, you know, new
uses for psilocybin, for example. So
we've just for example part funded a
trial that was for eating disorders and
another one I think for
obsessivecompulsive disorder and other
things like that and we very much
believe in supporting new research novel
research but we were not fans of
replicating trials that had already been
you know undertaken at least 5 to 10 or
more times in other markets overseas for
example end of life anxiety and stress
>> or there was a particular researcher who
did a trial with MDMA just for four
patients and it took I don't know more
than 5 years to complete things like
that we just thought well that's
statistically insignificant and one of
those researchers was one of the people
that really attacked us really strongly
like it was very very vicious and
personal.
>> Yeah. And because Peter and I were not
clinicians, that was another reason that
people thought, well, who are these
people? How dare they come into our
space as non-medical people and start
thinking that they could actually change
the regulations and how dare they think
that? And there was a lot of that
>> pushing back like go back into your box,
please, you know, you don't belong here.
>> So mistakes though. Mistakes.
>> Yeah. Well, I mean, maybe that was a
mistake, you know, but we we had a lot
of clinicians around us so that we were
also constantly having clinicians
presenting with us on webinars and
things like that. And we did that
deliberately because we didn't want
people to say, well, they don't know
what they're talking about. And so that
we had clinicians always appearing with
us when we were presenting, especially
if we're presenting to clinicians,
governments, and things like that.
I think other mistakes we made was that
we had a lot of people wanting to work
for us who had lived experience of
mental illness. And you know, look, we
all carry trauma and and I'm no stranger
to trauma. I'm the daughter and
granddaughter of Holocaust survivors.
And we all are carrying some kind of
trauma, whether it's our own, our
families, our lineage, collective
trauma. We're carrying that. But we were
attracting a lot of people to work with
us who didn't fully disclose all their
conditions up front. And so all of a
sudden there might be somebody who was
taking alcohol or would turn up to work
in a completely drunk state. And this
was something we'd never seen before in
other charities, you know, and I think
people were coming to us cuz they wanted
to heal their condition. And to begin
with, we wanted to be as inclusive as
possible with the people we had working
with us. And we still believe in that,
but we did have some very difficult
experiences early on where I guess we
were attracting people who still needed
to do more work on themselves rather
than working in a highpowered high
stress environment. And this is a high
powered when you're trying to change the
law.
>> Mhm.
>> You need people around you that are very
strong and who are resilient because we
got knocked down over and over. So I
would say you just have to be so
resilient and you can't let it all
affect you. And even the personal
attacks, you know, I found them very
hurtful
and I'm quite a sensitive person. And
there were times where I was literally
lying on the carpet crying because it
was just too personal. It was just too
much. I thought I was tough and had a
thick skin before this, enough of a
thick skin, but I didn't. And so I had
to bring in all the resilience of my
forefathers, my maternal grandmother
who' fled the Holocaust and all of that
started to become very youthful when
this was all going on. you can sort of
see that anyone who's a pioneer who's
trying to drive change is going to be
attacked and I hadn't really appreciated
that fully before.
>> Does anything else come to mind? So I
will underscore what you just said. very
common in
>> the
broadly speaking psychedelic space which
is incredibly understandable but it is
like the last or viewed as the last hope
for a lot of people for whom every other
intervention has failed.
>> Yeah. And for that reason, a lot of
people who want to help are in fact, and
this is again understandable, interested
in trying to mitigate some of their own
suffering,
>> but are not in a position where they can
sustain the type of intensity or
stress or volatility
in some of the work that is being done.
Right. It's just it's just not the right
timing for them. Not the right
circumstance. That's right.
>> And I would also say that for those who
haven't been exposed to the science,
it's another reason why
the effect sizes of these drugs on even
a small cohort, say 12 people, 15 and
whatever it might be, when you see these
dramatic reductions in
HAMD or whatever assessment might be
used for depression or PTSD,
>> what makes it all the more mind-boggling
is when you consider how long people
have had these diagnoses and how
resistant they have been to in some
cases dozens of interventions.
>> Yes.
>> And [clears throat] when you look at
some of this data, I think it was the
phase 2 data from maps looking at
complex PTSD, but the average and again
I might be misspeaking, but I'm I'm
directionally right. the the average
length of diagnosis
of severe complex PTSD was something
like 16 years 17 years right and then
you see for a [snorts] subset of that
group complete remission
>> correct
>> after two two or three sessions
>> 68%
>> yeah which also I'm pulling from memory
so this this is a dangerous business but
[laughter] when I did the maps when I
joined the I kind of audited I didn't do
it for any type practice myself, but I
sat in on the
MAPS international therapist training in
Israel, which was the first time
actually that any to my knowledge any
federal government had paid for or
supported at least financially supported
this type of training. And my
recollection is this was quite a few
years ago that after the last
administered medicine the remission rate
was something like 54 and then 6 months
later it climbed to 68. It went up and
again we're painting with kind of a
rough brush here. Maybe it was 65%. Who
knows? But the point is that people who
no longer met the clinical diagnosis of
PTSD, right? They went from like blind
shut, can't work a job to [snorts]
asymptomatic
grew over time. It did not go down over
time.
>> Yes, that's remarkable. That is a
remarkable feature.
>> It's crazy. It's just crazy to think
about. Like the durability is so wild.
And also, it's not a panacea, right? to
your point, it's like if you go back
into the same circumstances with the
same temptations and the same problems
and the same abuse or the same fill in
the blank.
>> Mhm.
>> It's not a magic bullet. And you know, I
really agree. I'm taking us a little
sorry off off on a tangent, but with say
Golan who's now at UC Berkeley, used to
be at Hopkins and I'm paraphrasing. She
can certainly speak for herself. I've
had her on my podcast.
>> We do too.
>> I believe these psychedelics open a
critical period. critical window.
>> The critical window within which you can
change long-standing beliefs and
behaviors.
>> That's right.
>> So, I think the integration and I mean
I'm working on a bunch of stuff related
to this right now actually outside of
psychedelics, but when you induce
neuroplasticity, right? So, suddenly
you've warmed up the clay and you can
shape it in a new way.
>> That's right.
>> The question is how do you do that?
Right. And it becomes a
>> a lot of the questions relate to
behavioral change.
>> They do. How do you set up the systems?
How do you set up the nudges? How do you
create the incentives? How do you, etc.,
etc., etc.,
>> right?
>> And because it's not a foregone
conclusion that you take these things
and you turn out better. It just isn't.
>> No, no, it's not. Though it is, you
know, to your point about the increased
remissions, when I started presenting on
this and I saw that was that New York, I
think it was New York Uni or John's
Hopkins trial that showed these
increasing remissions over time. That is
not something that would ever happen
with an anti-depressant. Usually what
happens with an anti-depressant is you
get an original improvement perhaps then
it plateaus. Then the doctor says well
we might have to try a different
anti-depressant or increase the dose.
Whereas in this case you have those two
or three doses
maximum. Then you're having the
psychotherapy and your remission is
increasing if you engage well with the
integration sessions.
And that means making those changes in
your life that you've just talked about
that are really important. Whether that
means exercise, nutrition,
you know, connecting with people who are
important for you to connect with that
are not going to bring you back into the
old patterns that you were in before.
>> All sorts of stuff about community and
social connection, I think, is really
important at that stage as well.
>> Yeah, for sure. What do you think
contributed to the TGA agreeing to the
offer to have David Nuts speak to their
employees? Like why would they say yes?
Cuz sitting here in the US, if I were
just to like ring up the 800 number at
the FDA and be like, you know what, got
a pitch for you. [laughter]
>> I don't think it would go anywhere. Now,
sure, I wouldn't call the 800 number,
but even still, it would not be easy for
me to get a yes to create a webinar.
Look, I had the mobile number of the
head of the TGA. I was lucky to have
that. Somehow I got that.
>> Sure. He or she loved that. [laughter]
>> I don't think he loved me having his
number. I didn't bug him too much, but
if things started to get roadblocked and
we could see they were getting
roadblocked, we might give them a call
and say, "What's going on here now?" Or
there was all sorts of governance things
that would happen. Like it was really
important, for example, that they
publish all the submissions, but it took
them a while to do so. At the moment, by
the way, we have a new submission in.
You can see our submission for end of
life stress and anxiety with psilocybin.
We're trying to extend the psilocybin to
end of life stress and anxiety because,
you know, virtual assisted dying is
legal in Australia. So, if people can do
that, then why can't they find peace
through psilocybin in Australia? So,
that's part of our argument. You can see
our argument on the TGA page and in fact
on our website on Mind Medicine
Australia, you can see all our
submissions
for these medicines to the TGA. But I
think really we were speaking to him. It
was getting to the really pointy end of
the final really probably what would
have been the final chance to get there
and and we'd put in the opposing
submission to the interim decision. So
the interim decision said no, we'd put
it in. We asked him if we could present
that we were were bringing David Nut to
Australia. So he said yeah. And then as
I said 10 to 15 people he thought would
turn up and then it was 140
>> 140
>> and not a dry eye in the room after
Vanessa spoke like literally everyone
was in tears. And I think it was really
her. I mean David was brilliant. Of
course he was brilliant but I think it
was her. I think it was the fact that
people could see a real life example.
Well, this is what's going to happen if
we keep denying people access to these
treatments. This then we could have many
more Franco occur. And of course,
>> there's many people who are taking their
own lives because they've given up hope.
>> And we want to give people hope and we
want to give them their lives back.
That's the most important thing in the
world we could have ever achieved.
What are some of the biggest challenges
still
>> now
>> in current day or that you foresee in
the next year or two? I just don't know
what the picture currently looks like,
right? Because it seems like there's a
grand kind of realworld experiment of
foot in Australia, right? which is like
okay we've allowed these authorized
psychiatrists and medical professionals
to
prescribe and supervise sessions with
MDMA and psilocybin
>> and
is the jury still out in the sense that
the government's like after x period of
time we're going to review all this data
and determine whether we want to
continue this or not or is is that not
the case is it open-ended
>> I mean I believe it's open-ended so we
do still keep having an ongoing dialogue
with the TGA. So we write periodically
to the TGA about some of the
bureaucratic roadblocks. So there are
some bureaucratic roadblocks. For
example, for quite a while until a few
months ago, there was a rule in place
that only clinical psychologists could
be the lead therapist. So you know
there's two therapists that usually sit
in the dosing with a patient.
>> Well, there was this criteria that it
could only be a clinical psychologist.
So we then put in a letter saying all
the reasons why it shouldn't just be a
clinical psychologist, why it should be
other psychologists, but also other
practitioners.
And so then that did get widened. And
every time there's a roadblock, we write
letters to the TGA showing the evidence
and research why that should not be the
case. And if necessary, we'll have a
call and we'll keep just trying to open
the door. Not to open it fully. That's
not our goal at all. We believe that
these treatments should be done in very
careful ways because
some of the patients going in for these
treatments, in fact the majority going
in for these treatments above ground in
clinical environments are very sick and
they need to be very well cared for. And
so they need to have proper screening.
They need to have top most well-trained
clinicians sitting with them. and they
need to have extremely good integration
processes and tools to go back into
their lives and to get real remissions.
But we don't believe that there should
be overly ownorous constraints. So now
we've also got a situation in Australia
where all of the clinics are videoing
the sessions. So there could be an
argument in the future that says that
one clinician with a patient if there's
a video there as well might be
sufficient. There's also group therapy
that we're looking at and we've we've
already started to look and I think some
authorized prescribers might have put in
protocols that might have group
integration in their protocol. So we're
very supportive of that. Other
roadblocks of course is the cost. So
there's still a lot of patients who
can't afford the upfront costs. So we
need to let them know about our patient
support fund. We need to let them know
that Medybank is providing their gold
members who qualify for these treatments
with pretty much the full cost of the
treatment which is really significant.
>> How much is the cost off the rack at the
moment? So at our clinic, so we've
started a clinic too with another listed
company called Inconex and our clinic is
called Mind Medicine Australia.
>> Listed meaning publicly traded company.
>> Yeah. So we as a charity have a half
share in this clinic with a publicly
traded company and it's called Mind
Medicine Australia Clinic and it's in
Abbottzford, a suburb of Melbourne and
we're using that as a real test case to
see how to build a best practice clinic.
So what what do we need to do? how much
supervision needs to be supplied. We
also use it as a wonderful resource
where some of our clinicians that we've
graduated through our training course
can go and gain supervision and
experience as well as in the other 20
clinics around Australia. So it's like
we're developing this sort of clinic in
a box, you know, protocol, I guess.
>> How much does that cost per person if
they depending on the compound maybe? So
we actually at our clinic only start
with people at one dose. So if a person
decides after one dose that it's really
not for them, they can withdraw because
in speaking with our authorized
prescribers, they preferred that
protocol and we don't want to force
people through it if they really don't
want to do it. And money is an issue. So
it starts at about $8,000 Australian
dollars, which is about 5,000, let's
say, US dollars
>> for one treatment including the
screening. Then the next one, yeah,
probably up to about $15,000 for three
doses and integration.
>> And that's the same for either compound.
>> Yeah, I think MDMMA might be slightly
more because it may be up to three doses
where psilocybin's up to two and that
includes the 3 to four months of
integration following the medicine
treatments as well. So, it's about a 3
to four month course that is costing
maybe up to about $25,000 Australian
dollars, about say $15,000,
something like that.
>> It's expensive, but it's not insane,
right? And I know it's out of reach of a
lot of people, but if people view it, if
they think of it as a pill, I'm taking
one pill and it cost me $5,000. And it's
like, okay, their reference point is
walking into a pharmacy, let's just say
here in the US, they have their
insurance and the copay is five bucks or
10 bucks and they get their 30-day
supply. So, they're like, "Wait a
minute, how is it possible?" But when
you realize, if it were to be framed,
I'm not saying this is the way to frame
it, but it's like, this is 3 to four
months of
very well-designed therapy, and by the
way, you also happen to get a few
powerful drugs along the way.
>> Yes. [laughter]
Then people be like, "Yeah, okay,
great." But when they think of the drug
first, they're anchored to a reference
they understand, which is probably some
very lowcost prescription that they get.
Yeah.
>> 90 days at a time.
>> No. Well, I mean, it is really important
to say that the majority of that cost is
therapeutic time like the medicine. So,
we've enabled the medicines to come into
Australia at the cheapest possible
price. Like the medicine is like a tiny
little percentage of the cost that I've
just mentioned. M
>> it's all about therapeutic time and
because there's two therapists involved
for some periods of that time that's
even more which is why one of the
reasons that we and not only we others
around the world also say well if
there's a video in the room does it
always have to be two therapists I mean
but it is a long treatment time as we
know so a dosing session can take 5 to 6
hours so maybe there needs to be some
overlap there
>> is there anything in process or have you
guys thought about methyline alone. You
know, Tren transcend Therapeutics was
recently acquired. I don't know what the
parent company is now planning with
methylone, but methylone is,
for lack of a better descriptor, it's
like the softer, gentler cousin of MDMA
who just comes in for a quick hello as
opposed to sitting down for dinner.
>> I love that.
>> It's like a 45 to 60 minute hello as
opposed to 4 to 6 hours. M
>> and as you mentioned it's like the cost
of well my opinion right I mean the cost
of synthesizing and purchasing these
things should not be exorbitantly high
although there are there are certain
>> and depending in where you where you are
in the world there are some companies
that would like to make that
>> as expensive as possible but that's a
whole separate conversation
>> absolutely
>> but putting that aside putting kind of
pharma shenanigans to the side like the
pills shouldn't be expensive
>> not at all
>> the materials but The therapist time is
expensive
>> very
>> so if you could look at comparing say
methylone and its effects which have
been quite impressive I mean looking at
non psychotherapy coupled
dosing right because maps like us at the
time got itself into all sorts of
tangles
because the FDA on our side does not
know how to think about standardizing or
regulating psychotherapy. So if the drug
is inextricably tied to psychotherapy,
the FDA is kind of on some level
forced to respond with we don't know how
to deal with this, so we're going to say
no. I mean, there's much more to the
story
>> because that's not their expertise.
They're a medicine scheduling bureau,
[laughter]
>> right? So then transcend said, "Well,
let's just look at what happens with the
dosing of the medication." And even if
you had though a therapist in the room,
which is not a bad idea, then you have
something that is possible within a 60
minute.
>> Yes.
>> Or let's just call it 60 to to 120
minute window, right? Which should
ostensibly lower the cost really
substantially. And I know this probably
wouldn't convince the TGA, but like my
perspective too is like look, you're not
tripping your balls off when you're on
methylone or MDMA. Frankly,
>> not at all. Most people could have a
conversation. They're probably not going
to want to work on a computer, but
there's not as much distortion as you
would experience on something like
psilocybin.
So, when you have, let's just say, six
people in a room plus one therapist or
two therapists, you also for each
patient have five other witnesses.
>> Yes.
>> Yes. They're in an altered state, but
it's not like they're seeing goblins
doing jumping jacks all over the room.
>> [laughter]
>> It's not that kind of
>> perceptual distortion.
>> I'm all for that, Tim. I mean, like, so
one of the things that I think I
recently mentioned to you that I went to
Dave Asper's Beyond event in Austin,
Texas, and there happened to be a stand
there for Cana, and I don't know if
you're familiar with Cana.
>> Cana African, I believe.
>> Yeah. It's an African medicine. It's not
cannabis, but it's like an African leaf
or something
>> with a K. Anyway, and I came across
through a friend of mine who was there a
substance called Cana Lift. I think it's
called Lyft. And it's like MDMA, but
it's shorter lasting. It only lasts a
couple of hours, maybe 90 minutes to 2
hours. And I just thought actually and
it's natural as well, which I really
like. And I thought to myself, wow, this
is really good. I I agree with you. I
mean, obviously ketamine is being used a
lot and people go in and and have a
ketamine session certainly in the US.
It's not as common in Australia, but a
lot of therapists in the US are using
ketamine for depression. But the problem
about ketamine is that it needs to be
used over and over in most cases.
>> Even bigger problems, it has very, very
high addiction potential.
>> Correct.
>> I've seen a lot of lives unravel because
of ketamine. has its place. If there's
acute suicidality, I do think that IV or
intramuscular ketamine has a place, but
it is very easy to abuse.
>> Yeah,
>> very, very easy to abuse. Yeah, the Ken
check out
>> check it out. Yeah, I'll send you a
link.
>> I took a look at it quite a few years
ago. The synthetic allnatural thing is
an interesting conversation just because
I would say that I am interested in all
natural to the extent that
you might be throwing some of the baby
out with the bathwater when you move to
say Ibegan from Ibogga, right? And I
certainly know a number of researchers
and certainly plenty of practitioners
who would take that side of things
simultaneously. Part of the reason
scientists and pharma like to isolate is
because
you have a less in some instances a less
muddied picture of things. You have
fewer variables. But in the US for
instance, I don't know what the status
is in Australia
>> or depending on who you ask.
>> Oh yes.
>> Was viewed as this savior of the people
who want to get off of opioids [snorts]
and prescription drugs. But metrogenine
or metroinine which is found inratom. Lo
and behold if you use it chronically
can put you into a dependent state where
you need rehab to get off of cratom.
>> That's crazy. Right.
>> Right. And I know people who run
rehabilitation clinics and so on. And
like if there were maybe there is a
chart I don't know where you would find
it but anecdotally talking to people who
run these type of clinics or people who
run clinics offering different services
part of which is detoxing from various
types of drug dependencies like is up
and to the right it's like AI stocks
they are matched. I would tell people
all natural can be very powerful and it
also can be in some cases poorly
understood because there aren't as many
financial incentives if there isn't
something that can can be patented,
right? And like we get into very
slippery territory here. But
>> I would also say in the case of
ketamine, like
I'm not a doctor. I'm not giving medical
advice, but
>> if you look at say Johnson and Johnson
and Spado, sure it's esetamine, but
they've created a maintenance model with
this drug. But I would say if you suffer
from a serious diagnosed mental illness
then obviously follow the advice of your
doctor. But if you are considering
different options and you happen to be
in the US and one of the few legal
options available is ketamine, I would
encourage with the input of your doctor
to look at
less chronic use as an option.
>> Definitely. And you've got Phil Wolson
and others who have certainly written a
lot about this. You have John Crystal at
Yale who's looked also at IV and
intramuscular use of ketamine where you
may just need a few rounds, right? You
may just need one round.
>> Well, you might just need to have
psilocybin therapy instead.
>> Well, there's that, [snorts] too. Yeah,
we have some legal checks to make.
>> Oh, no. I get I get that at the moment.
>> At the moment, for sure. I mean, look,
ketamine would not be in my top five
list,
>> nor mine. However, there are two huge
caveats there. Look, it is one of I
believe it's still on the World Health
Organization's most essential medicines
list. This is a very useful drug as an
anesthetic. I mean, it's a dissociative
anesthetic. So for instance, if you have
any history of using alcohol, even to
take the edge off, certainly if you have
alcoholism or alcoholism in your family,
ketamine is like the dissociative
turning off of feelings you don't want
that you get from alcohol times 100.
Ketamine that is part of the reason why
it can be so addictive. However, if you
have chronic pain, this is I know not
within the sphere of mental health, but
for certain types of chronic pain,
ketamine is incredible.
>> Yes.
>> In terms of very few rounds with very
durable benefits.
>> Yeah.
>> And in fact, I really dislike ketamine
in general. My subjectively, like
personally, it's not really my thing.
But I was getting so many questions
about ketamine. This is probably 10
years ago. And I decided, well, look,
I'm going to follow basically the Yell
protocol and I'll get the whatever it
is.5 milligs per kilogram or whatever
the magic doses that everybody took as
gospel, even though it was like an
informed kind of guess on the part of
John Crystal and his colleagues,
whatever became the dogma, I was like,
"All right, I'll do at least one,
probably two two week sequences of
infusions, so at least I can speak
firsthand to the subjective effects.
and
the experience, right? Like the
phenomenology of the experience. I'll be
able to answer some questions about it.
>> Mhm.
>> And went in and the clinicians were
good. This was in Austin. And you have
to be careful. There are a lot of fly by
night operations, but I did my homework.
I kind of know how to vet this stuff.
And the clinicians were so baffled by me
because I went in and I had no anxiety,
no depression, right? And each time I
went in, which was multiple times a
week, they would ask me to fill out this
assessment to determine my current
state, my how they would score me for
anxiety and depression. And I just kept
getting more anxious, not really
depressed, but more and more anxious and
maybe mildly more depressed. And the
reason was [laughter]
I had a really, really busy two weeks.
So, it's like I'm preparing for a
podcast with LeBron James, but then I
have ketamine and then I forget my
backpack and like my short-term memory
is [ __ ] and I'm like misplacing all
this [ __ ] and then have constipation so
it's like hard to sleep and I'm like
this stuff is terrible. Right? So, every
time I went in I was getting more
anxious and they're like this is very
confusing for us. We really don't know
how to how to make any sense of this.
And I got to the end of it and I was
like god that stuff is weird and it is
not for me. I was just like look I can
handle it. like I went like I pushed it
with a lot of clinical supervision. The
IV allows you to do some very
interesting things that you can't do
with intramuscular. Intramuscular like
you you hit the golf ball and the golf
balls hit like you're gone. But with the
IV you can dial it up and down and
experiment with things like interacting
with the therapist at different dosages.
>> Have you heard about IVD 5me?
>> I know quite a bit about IV NNDMT
>> where they extend it out to about an
hour. There's been some research at
Imperial College. Would I do it? I think
I'd be open to it.
>> I don't think that's automatically a
free lunch. I mean, that's gonna be
pretty intense.
>> Yeah.
>> But, you know, I'd be open to it. On the
ketamine side though, the reason I
brought up this whole story preparing
[snorts] for podcasts and getting
anxious and being kind of annoyed that I
had to go in and do this thing because
I'd committed to this experiment [gasps]
is I I finished my first series of
infusions and I was like, "All right,
never doing that again. That was a total
waste of time." [snorts] And then I
noticed about a week later I had this
really horrible pain in the like middle
of like my thoracic musculature in my
kind of midback. And this had been from
a horrible injury
15 years ago, something like that. You
where I basically almost tore my lad off
my back. Really bad accident. And it had
plagued me ever since. And I would sit
there and I'd be like, "Oh," and
sometimes I couldn't turn, sometimes I
couldn't cough, sometimes it would hurt
to breathe deeply. I mean, it was really
this chronic plaguing injury. And after
I had that
whatever it was, week or two weeks of
infusions, that went away, never came
back.
>> Wow.
>> And that is one of the indications for
ketamine is certain types of chronic
pain. And I was like, "Holy [ __ ]
amazing." I was like, "Okay, there's a
place for it." That was worth it.
>> Wow.
>> I really didn't like that experience,
but it was worth it. And I do know
multiple people who are like, "I'm going
to blow my head off tomorrow."
And they go in and they have an infusion
[snorts]
or intramuscular injection and at the
end of the session, they're like, "I
don't know what I was so upset about." I
mean, they're able to look at it in a
dispassionate, more well, dissociated
obviously capacity, right? They're
almost an observer of their own state
and the stories they were telling
themselves. So for that also I think
it's useful. But yeah, personally it
wouldn't be on my top five.
>> No. No. Well, it's not being used much
in Australia, but I feel there's going
to be huge shifts globally over the next
few months and that there's going to be
psilocybin probably through compass
pathways and sona will be registered. I
think is it resilience? What's the name
of maps now? I can't remember now, but
>> they keep changing names. I think it's
resilient. resilience. I think that's
going to come through as well,
>> especially given that the president's
given that executive order. I think that
potentially by mid next year, who knows
what's going to be registered and
>> yeah,
>> the whole landscape's probably going to
change and a lot more countries
hopefully going to be following
Australia and hopefully there'll be less
bureaucracy and we can have way more
people being treated. Yeah, a lot of
people may not realize that Australia is
a very
fascinating
landscape when it comes to conducting
certain types of science and globally
a lot of clinical trials from companies
around the world have gone to Australia
and China.
>> Those are kind of like the two places
you want to do it. That's kind of fun
for people to check out if they if they
weren't aware like there is a global
market for conducting clinical trials
and Australia is one of the best places.
>> Yeah.
>> I wanted to come back to advice for
advocates in other countries and things
you might do differently. And you were
mentioning that you're very persistent
which you are.
>> You and your husband. So here's another
quote from this is abc.net.au. Hey, you
and I think [clears throat and snorts]
you'll get a good chuckle out of this.
All right, so here's the quote. I
actually had to on several occasions say
to staff, look, I know they're driving
you crazy, put their approaches in the
way they work to one side. Think about
the medical criteria and the scientific
criteria and the regulatory issues only.
And I also counseledled Mind Medicine at
some stages that they were perhaps
working against their own case by
frankly being so aggressive. I lost
count of the number of emails they would
have sent staff here. [laughter] I think
this is Professor Scarat.
>> Yeah, that's right. told background
briefing that he did provide MMA with
the names and public phone numbers of
the chief health officers in each state.
[laughter]
Hilarious. The committee of experts and
state regulators that advised TJ were
similarly displeased by MMA's outreach
according to a TGA in so you're a
[clears throat] force of nature. You
guys have have accomplished some amazing
things. Were there any cases of pushing
too hard? Right. Because there are cases
when people like push with me. If they
hit me from like 17 different
directions, I'm like don't like it. to
brute force and I'm like blacklist I
won't engage right
>> which is not to say that you should have
done anything differently but I am
curious like are there cases where
you're like all right I should have
waited an extra week I should have
approached that slightly differently how
do you think about that
>> I think in this case I mean certainly I
know that me personally
can be too pushy at times and I've had
to really scale that back and one of the
things that the medicine has taught me
is to be more accepting and I have
become more accepting, you know. So, if
a door or something doesn't seem as open
as I first thought it was or if it
really feels really shut, I just don't
go back and knock on the door as much
anymore and I just go, "Okay, there's
other opportunities. I'll go to them
instead and I'm going to go for the
lowerhanging fruit." So, that's that's
just me personally nowadays. I'm
much less driven about that than I was.
And I think it's better.
>> Mhm. But in terms of this particular
campaign, I don't really think that
anything less would have been enough.
>> And I feel that we had to keep pushing.
And even my husband who's less pushy
than me,
>> he's English, you know, [laughter]
>> I'm Jewish. I've got a lot of hutbah.
You know, I was
>> I was brought up with a grandmother who
invented the first foldable umbrella.
She was a woman in the 1920s doing stuff
that was way ahead of her time. But even
he says that you know we had to do what
we had to do. We had to just keep
pushing and moving forwards and we did
have to knock on every door and we had
to use every bit of the networks that we
developed over decades to achieve what
we achieved. But it was all done
because of the data and science. It
wasn't done because we pulled some
favor. That was not the case at all. We
all have this in our lives. We all have
people in our lives who are suffering
immensely and we owe it to them to push
for the most safe and effective options
available and a lot of safe and
effective medical options are not
available. They're being withheld from
the public and this is only one example
of that. And so we all have to push as I
say we all have to become our own chief
medical officers. We have to work out
what's going to work for us, what's
going to make us whole and healed
>> so that we can live our best lives
possible. And for me, that's the reason
why I'm here. You know, like I saw an
article by you.
I read it. I immediately felt inspired.
And that has led to everything else that
we've created. So, you know, we blame
you entirely for all this [laughter]
and all the plaque that we cough.
>> Yeah. You know, I can say this now
because like to see that
>> part of the journey.
>> It's just extraordinary, you know, and
we receive these letters now where
people are just like, you gave us our
lives back.
>> Yeah.
>> We've given people their lives back,
Tim, and that's something that you
should be so proud of because if it were
not for you, I wouldn't have even known
about this. Certainly not at that time.
I would have probably discovered it at
some point. But there's always a thing
about timing.
>> Yeah.
>> And that was really important timing.
And we all have to just if we really
believe that something has to be done,
then we just have to go for it and we
can't let anything stop us. I've told
you the story in my TED talk, how
singing together changes the brain. I
was told as a 14-year-old girl never to
bother having singing lessons by my best
friend. I talk about in my TED talk and
one of the great things I learned was to
never let anyone snatch your dreams
away.
>> And you can't.
>> Yeah. too important.
>> Thank you for saying that, everything
you just said. And man, we are here for
such a short time,
>> right?
>> It's like you got to get after it
or not, but you got to do your thing, I
suppose. Tanya, so nice to spend time
with you. Thank you for making the time.
>> My pleasure.
>> Where would you like people to find you
and Mind Medicine Australia? And do you
have any asks of the audience? Is there
anything you're trying to accomplish at
the moment where maybe there's someone
listening who may actually be able to
help or hold the keys to something?
>> Well, I have a couple of asks. So, one
of them is that we have our patient
support fund and we're a registered
charity. So, all donations to us
depending on what tax vehicle you're
giving through can be taxdeductible
where so we have full deductible gift
recipient status. Certainly in
Australia, we also have people from
overseas who donate to us regularly. And
our goal is to raise at the moment $2.5
million so that we can really enable a
lot more patients to have access to
these treatments who otherwise couldn't
afford the upfront cost. So we're
talking here about helping support
veterans, first responders, single moms,
people who demonstrabably can't afford
the upfront costs of these treatments.
That's my first ask. would people find
if they're interested in considering
that is that mindmed
medicineustralia.org.au
is that the place to go or
>> yeah mind medicineaustralia.org.auu
>> and then the second thing is if you're a
clinician or therapist out there and you
really would like to work in this field
and you want to learn from the world's
best well we have the most extraordinary
global faculty that is teaching our
certificate in psychedelic assisted
therapy. So people like Bessel Vanderol,
Gabbor Mate, who I know is a great
friend of yours, Tim and mine as well.
People like Bill Richards and David Nut
and Rick Doblin and all those people are
on our faculty, Jim Wolson, other lots
lots of people that you know, Wayne
Davis. So these people you can study
with through our worldleading
certificate in psychedelic assisted
therapies. And our next intakes are in
February and July of 2027. Our current
intakes full. All our intakes get booked
out, but we really welcome you and we
have people coming from all over the
world to study with us. So, we've got
people from Switzerland, you know,
Europe, the US, Canada, even from the
United Arab Emirates and Asia. Now, we
feel there's huge markets potentially
opening up in Asia and the UAE.
>> And so, we're seeing quite a few
clinicians coming into our training from
those regions.
And just look us up. We've got an
amazing website. It's an amazing learn
section. Everything you could ever want
to learn about psychedelic assisted
therapies is on our website. Tim, I've
got an ask for you, but you don't have
to say yes, and that is we'd love you to
join our advisory panel, but we can talk
about that offline. We also have an
extraordinary webinar series, and it's
free. And the next one's on eating
disorders. We just had Dr. Peter Lavine
and before that we had Dr. Gabbor Mate.
And
>> is that Peter Lavine walking the tiger?
Peter Leavine. Yeah, that one. And later
in the year, we've got Bessel Vanderolk
and I think we've got a Dick Schwarz one
coming up as well. So, we have this
extraordinary faculty. We have
extraordinary people working with us.
And just reach out. We're really
friendly. We have a huge community and
we're building a movement that's
building this massive other movement
that we just we just need a massive
movement globally that is saying we all
need to have access to treatments that
can heal us. But bigger than that, our
bigger reason for being here was to make
sure that the worried well that people
like you and I, Tim, could get access to
these treatments to raise our
consciousness and to expand our beings
and for us to really learn and become
curious because I think one of your
questions is commonly, what would you
put on a billboard? And I would put be
curious
>> and [clears throat]
these medicines really help us to be
curious. And if we can awaken people's
curiosity in a world that is so
dominated by AI, we just need to go back
and be curious and start to ask our own
questions, not just to AI, but to
ourselves and to what's here.
>> So
I would say to everyone, let's just keep
asking questions and not
outsourcing ourselves to all of the chat
bots and all of the robots. [laughter]
Yeah. Well, sometimes it's a good idea
to take a break from going outside for
entertainment. Go inside for
entertainment.
>> Entertainment. Entertainment.
>> There's a lot to be curious about.
>> There's so much inside. So much inside.
And that was probably the greatest gift
of the medicines was it really taught me
to explore my inner terrain.
>> Mhm. I'd always been such an extroverted
I was very introverted as a child but
then I was pretty extroverted as a
performer and I still you know I'm
pretty extroverted person but for me to
be able to go inside and to actually
explore every single night I lie in bed
and I just explore what's going on
inside I couldn't have done that without
these medicines they gave me that
>> yeah it's a category of catalysts that
that is very interesting many people who
I think listeners would associate with
meditation actually never took up
meditation until they had
their mind
>> changed
>> the cosmic egg cracked open
>> by [clears throat] psychedelics which is
not to say you have to start with
psychedelics you don't
>> but many of them have been greatly
informed by psychedelics you know Ramdas
certainly being one
>> primary example that you mentioned and
there are many many others
>> well one of the great things that he
said to us when we were with him was
we're all walking each other home.
>> And I think that's one of the really
most important things that these
medicines teach you that really we're
all we're all here together. We've come
from whatever that place is. We're going
back to whatever that place is. And
we're here for a really short time to
your point. And so why can't we all just
reach out a hand, get out from behind
our boxes and screens and start walking
each other home? So, I write songs about
that. [laughter]
>> That's amazing. It's too bad I never got
to meet him. I did watch the documentary
about sort of the last chapters in his
life. What an incredible human.
>> Amazing. Becoming nobody. Have a look at
that one.
>> Becoming nobody. Exactly. Tanya, thank
you so much for the time and thank you
for doing what you do. Please say the
same to your husband for me. and the
website. I'd like you to add anything
else that you'd like to, but mindmed
medicineustralia.org.au.
That's for the trainings for the
resources. If you want to consider
donating and supporting this nonprofit,
you can find everything. My
understanding is at that website.
>> Yeah, I have a personal website, too.
So, that's Tanya Dong. T A N I A D E O N
G.com. My personal website. Please feel
free to reach out on any platform. I
like LinkedIn, but there's lots of
others. And I just want to just really
say to you, Tim, that I just want to say
a huge shout out to you
for everything that you've done, not in
just in this field, but for your
willingness to try to question, to be
curious, and to to really try to hack
yourself and to find things that you can
share with others that are going to work
for everybody. And
honestly, if it were not for you, and
you can see this in multiple interviews
that I've had,
probably we wouldn't be sitting here
having this conversation. Australia
probably would not be leading the world
in this field. And I just want to thank
you for all the resources that you give
to people every single week. I love your
five bullets.
>> Thank you.
I open [laughter]
a huge testament to you and you just as
you said when we first met you never
know where these things are going to end
up
>> but I want you to know that your work
helped change a whole nation and not
only a whole nation but because our
nation has changed that has changed the
whole world and there's there's a real
possibility now there's a real hope for
everyone that we can actually heal some
of the immense suffering in our world
and that brings tears to my is just even
saying it because we've seen the
suffering and we have seen as you would
all the time the most devastating
letters and emails from people who've
they just deserve a chance.
>> Yeah, I do.
>> And that was the reason we did this. And
I think in spite of us being pushy, our
hearts were always in it for the right
reasons.
>> Mhm.
>> And I think people realized that.
>> Well, thank you Tanya. Thank you for
saying that. And you're right that often
times I mean the fible Friday right I've
been writing this newsletter for [sighs]
>> god I don't know 10 15 years however and
do it every week and sometimes I'm just
like is anybody reading this I
[laughter] really am not sure it just
gets fired off and because of the format
I'm just kind of like I really have no
idea what is resonating what is landing
so I have to just follow my own
curiosity and just like if I find it
compelling if for whatever reason, even
if I can't justify it, it's tugging on
me in some way, I'm like, "All right,
look, maybe there's at least one other
person out there who might resonate in
the same way. Let me give it a shot." I
mean, there are 8 n billion, whatever
the number is, people on this planet.
There has to be one other person who
speaks English this might get to. And
thank [snorts] you for saying all of
that. really admire you and what you've
done with your husband and everybody
associated with with MMA and you know
the people who also said yes at the TGA
and everybody involved. Mhm.
>> It's such a beautiful story and the fact
that you were an outsider, that you
weren't steeped in this from day one and
you were able to just experiment and
test and cold email and offer to sing
and fly to freaking Wisconsin, the land
of cheese. Like most people are like
Wisconsin, isn't that where people eat a
lot of cheese? and to move mountains,
right, bit by bit by picking the right
place to stick that Archimedes lever.
It's a really inspiring story. And
>> part of the reason I wanted to, and I've
already said this in one way, but have
you on this podcast was because I think
there are many people out there who
underestimate how much they can do if
they just kind of increase the elbows
and get after it. And it's like, yeah,
you're going to make tons of mistakes.
Yeah. I'm sure you'll piss somebody off.
Yes. Yes. Yes. And but you might also
just make a huge thing happen.
>> Exactly. And do you know what? You never
know until you ask. And most people
never ask.
>> Yeah.
>> And you know what? All you have to do is
ask. And it's amazing how many people
say yes. Like literally just about no
one has said no to us to to join our
advisory panel. Literally just about no
one we've ever asked to do a webinar has
said no. People want to support good
causes and good, you know, good
pioneering efforts. We so need this. We
are living in a world that is becoming
more and more boxed in.
>> Yeah.
>> So, we need all of you out there to just
grab your dreams, ask for help, and then
set them on fire. Like, just not in a
bad way. Sorry. Set them on fire in a
[laughter] really good way.
>> I think I think they get it. Yeah. Yeah.
No arson endorsement on this podcast.
>> I'm not very good. I always mix my
metaphors like that. But [laughter]
>> so TLDDR, get after it, folks. We're all
going to be dead and dust no time flat.
So
>> exactly. What have you got to lose?
Seriously, what have you got to lose?
>> Ask for it.
>> People can find you at
mindaustralia.org.auu
and your personal website, which you've
mentioned, your name.com. And to
everybody listening, we will have show
notes as per usual at tim.blog/mpodcast.
Just search Tanya. I believe you are the
only Tanya that I've had on the podcast.
Tia, and you'll be able to find
everything we talked about, all the
people, all the documentaries, all the
organizations, etc.
>> Yeah, it's all there.
>> We'll put it all in the show notes. And
until next time, as always, be a bit
kinder than is necessary. Just try to be
a little bit kinder than is necessary.
>> Loving kindness
>> to others, but also to yourself.
That voice that you put out should echo
if you're being compassionate. The voice
that goes in. Do your best. I know it's
hard. Thanks for listening everybody.
Thanks for tuning in.